COGT
Cogent Biosciences, Inc.
$38.69
+0.21 (+0.55%)
At close · Jul 2
Market Cap
$6.61B
Shares
170,868,004
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$38.69
Open$38.50
Day$37.82–39.50
52W$7.18–43.73
Avg vol 30d3.0M
Short int13.5M · 7.9% float · 5.8d
Short vol55%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+20% above
+
Price vs 50-day avg
+11% above
−
RSI (14)
70 · overbought
+
MACD trend
positive
+
52-week position
86% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $35 › 200d $32 — 50d above 200d
−
Institutional flow
2 of 307 funds reported for Jun 30 · net -11 sh shares
◦
Insider flow
No net insider activity over 90 days
−
Short interest
7.87% of float · ▲ +16.8% MoM · 5.8 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
307 holders — near 3-yr high, broad support
Fundamentals
Weak
−
EPS growth
−11% Y/Y
−
Free cash flow
$-266.0M
+
Balance sheet
net cash $89.1M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+20% above
Bullish
Price vs 50-day avg
+11% above
Bullish
RSI (14)
70 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
86% · near high
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $35 › 200d $32 — 50d above 200d
Institutional flow
Distributing
2 of 307 funds reported for Jun 30 · net -11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.87% of float · ▲ +16.8% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
307 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $7
Now $39 · 86%
52-wk high $44
vs 200-day avg +20%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COGT
this stock
Cogent Biosciences, Inc.
|
$6.61B | +8.9% | — | — | 7.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COGT | +1.8% | +19.9% | +8.8% | 0.0% | +8.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +0.4% | +21.2% | +0.8% | +0.2% | -0.3% |